Today, it is one of the most active battlegrounds in biotechnology, with at least eight companies competing to cure it using completely different molecular approaches.
The race to cure alpha-1 antitrypsin deficiency now includes eight biotechs and surprising clinical results - SinapticaFor decades, alpha-1 antitrypsin deficiency (AATD) was a genetic disease almost forgotten by the pharmaceutical industry. Today, it is one of the most active basinapti.ca